Pfizer said Tuesday it plans to file for full U.S. approval of its Covid-19 vaccine with German drugmaker BioNTech at the end of this month. If the FDA signs off, the company will be able to market the shot directly to consumers.
In its earnings report, Pfizer said first-quarter sales of its Covid-19 vaccine was $3.5 billion. It reported earnings and revenue that beat Wall Street’s expectations.
Here’s how Pfizer did compared with what Wall Street expected, according to average estimates compiled by Refinitiv: